Why the study?
Does live attenuated polio vaccine provide immunogenicity and what are its transmission dynamics in nonisolated infants and children?
Does live attenuated polio vaccine provide immunogenicity and what are its transmission dynamics in nonisolated infants and children?
This early field trial evaluated the immunogenicity, intestinal infection rate, and transmission of live attenuated polio vaccine in nonisolated children.
Early cohort data on polio vaccine immunogenicity and transmission in nonisolated children; leaves open need for controlled trials to inform use.
Until the year 1958, reports were available only on small numbers of persons vaccinated against poliomyelitis with live attenuated polio virus. Practically all information had been obtained from isolated or semi-isolated groups in institutions. Early in 1958, we began one of the first field trials with live polio vaccine, a controlled study of vaccination in nonisolated infants and children of the city of Bern, Switzerland.1Since then, more than 80,000,000 people in various countries have been vaccinated with live poliovirus, and many of the problems associated with this form of vaccine have been solved. The purpose of our study was to obtain information about the following questions raised by this new method of vaccination: The immunogenic properties of the live avirulent polio vaccine The rate of intestinal infection and the duration of virus excretion The spread of the vaccine virus from vaccinated persons to nonimmune contacts
No takes yet. Share an insight, caveat, or question.
F. Buser (1961) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: